Episode Details
Back to Episodes
May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B
Description
Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on tebipenem, AstraZeneca's Imfinzi NMIBC approval, CVS restoring Lilly obesity drug coverage, BridgeBio LGMD data, Kardigan IPO plans, and ASCO 2026 abstracts drop.
Visit us at www.thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, bepirovirsen, GSK, Ionis, hepatitis B, functional cure, Spero Therapeutics, tebipenem, oral carbapenem, cUTI, CVS, Eli Lilly, Zepbound, Foundayo, obesity drugs, AstraZeneca, Imfinzi, durvalumab, bladder cancer, NMIBC, BridgeBio, BBP-418, LGMD, muscular dystrophy, Kardigan Therapeutics, MyoKardia, Secretome Therapeutics, Duchenne, ASCO 2026, Trump drug pricing, MFN, Akeso, Novo Nordisk, Merck, BioNTech, Moderna, Lilly, Sanofi, BMS